Rethinking Obesity: Novo Nordisk's Latest Initiative Urges Singaporeans to Treat, Not Blame
'Beyond the Scale' focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based care.
SINGAPORE - Media OutReach Newswire - 27 June 2025 - Imagine a chronic disease affecting more than 600,000 people 1-3 in Singapore — yet often misunderstood, overlooked, or surrounded by stigma. This is the reality of obesity today. For many, outdated perceptions and delays in care have created barriers to support and treatment. Today, a new initiative is calling for a shift — to change how we think, talk about, and respond to obesity, through a lens of science, empathy, and early intervention.
Breaking the Myths: A Public Health Reframe
"Just eat less." "Try harder." "It's a lifestyle choice." These are more than just phrases — they reflect a deeper misunderstanding of obesity. Today, a bold new initiative, seeks to challenge those misconceptions and open the door to a more compassionate, evidence-based conversation. "Beyond the Scale" launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, but as a complex, chronic disease. The initiative invites the public to go beyond — beyond stigma, beyond myths, beyond labels — and recognise obesity for what science confirms it to be: a multifactorial health condition that deserves understanding, early intervention, and clinical care.
Led by global healthcare company Novo Nordisk in collaboration with local healthcare professionals and patient advocates, "Beyond the Scale" is a disease awareness initiative aimed at driving a shift in how individuals, communities, and healthcare providers approach obesity management.
"We believe it's time to shift from blame to understanding," said General Manager, Mr Vincent Siow of Novo Nordisk Singapore. "Obesity affects 1 out of 9 people in Singapore 4, yet it's still too often seen as a matter of willpower. The reality is that obesity is a complex, chronic disease driven by biology, environment, and unequal access to care. 1,5 It's time we treat it with the seriousness it deserves — and we are proud to lead that conversation and drive meaningful change through the "Beyond the Scale" initiative.
Why This Matters Now
The 2021–2022 National Population Health Survey reveals the highest obesity rate (15%) among adults aged 40 to 49, while 43.3% of residents aged 18 to 74 had abdominal obesity, which increases with age and peaks between 50 to 74 years. 6 This is compounded by the fact that perceptions persist about obesity being a personal failing, discouraging individuals from seeking help, delaying diagnosis, and compounding the health burden on families and the healthcare system.
Obesity significantly increases the risk of cardiovascular disease (CVD), type 2 diabetes, and chronic kidney disease (CKD) 7, all of which already place a growing strain on Singapore's healthcare infrastructure. The economic impact is substantial: in 2019, metabolic-risk related diseases, including obesity, diabetes, hypertension, CKD, and cardiovascular conditions, cost Singapore S$2.20 billion. 8 Of this, S$642 million were healthcare expenditures 8, and excess weight alone accounted for an estimated S$261 million in annual medical and absenteeism costs. 9 Without decisive public health action, these obesity-related comorbidities are poised to escalate into a major societal and economic burden.
"This is not just a personal issue — it's a public health priority," said Dr Ben Ng, Arden Diabetes & Endocrine Clinic. "We know obesity changes how the body regulates appetite, energy storage, and metabolism. It's a disease, not a choice. Science supports this — and our response should reflect it."
The Science Behind the Message
Obesity is not simply about calories in and out. Research confirms it involves neuroendocrine (hormonal), genetic, and psychosocial factors, making it both preventable and treatable 10.
Studies show that in Singapore, weight stigma is often driven by the belief that obesity is a personal failing, lack of willpower, or lifestyle choice leading to delayed treatment, reduced care-seeking, and poorer health outcomes, particularly in managing chronic conditions such as cardiovascular and kidney disease. 11
Beyond Labels, Toward Lasting Change
"Beyond the Scale" is more than a slogan — it is a call to treat obesity as the complex, chronic disease that it is. To move away from blame, appearance-based judgments, and oversimplified narratives, toward empathy, science, and sustained health. It is an urgent appeal to rethink, retrain, and rehumanise the way we support individuals living with obesity.
"The earlier we intervene, the better the outcomes," said Dr. Ng."Obesity is not a character flaw. It's a disease. And it's time we responded with the same respect, science, and care we give every other chronic condition."
"Beyond the Scale" aims to:
Raise awareness of obesity as a chronic, multifactorial disease.
Reduce stigma and myths that hinder early care.
Encourage timely, evidence-based conversations with healthcare professionals.
Promote empathy and science within the medical community.
Support patients with tools to take charge of their health.
Singaporeans can participate by:
Visiting [ www.truthaboutweight.sg ] for factual resources, use a BMI measurement tool, and locate a nearest weight management healthcare professional.
Starting honest conversations with GPs, nurses, and pharmacists.
Sharing content to help dismantle myths and support loved ones on their health journeys.
1. Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508.
2. World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity
3. World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/
4. Lee, Y. V., & Tan, N. C. (2014). Obesity in Singapore: An update. The Singapore Family Physician, 40(2), 11–16. https://cfps.org.sg/publications/the-singapore-family-physician/article/71_pdf
5. World Health Organization. (2024). Obesity and overweight. WHO.https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight As accessed on 22nd May 2025.
6. Ministry of Health, Singapore. (2022). National Population Health Survey 2022 Report. https://isomer-user-content.by.gov.sg/3/28c3b8f9-9216-46be-8fc9-b614098666a9/nphs-2022-survey-report_final.pdf
7. Cohen JB, Cohen DL. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome. Curr Hypertens Rep. 2015 May;17(5):34. doi: 10.1007/s11906-015-0544-2. PMID: 25833456; PMCID: PMC4427189.
8. Tan, V., Lim, J., Akksilp, K. et al. The societal cost of modifiable risk factors in Singapore. BMC Public Health 23, 1285 (2023). https://doi.org/10.1186/s12889-023-16198-2 (2.2 Billion)
9. Junxing C, Huynh VA, Lamoureux E, Tham KW, Finkelstein EA. Economic burden of excess weight among older adults in Singapore: a cross-sectional study. BMJ Open. 2022 Sep 16;12(9):e064357. doi: 10.1136/bmjopen-2022-064357. PMID: 36113947; PMCID: PMC9486358.
10. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. PMID: 28489290.
11. Goff AJ, Lee Y, Tham KW. Weight bias and stigma in healthcare professionals: a narrative review with a Singapore lens. Singapore Med J. 2023 Mar;64(3):155-162. doi: 10.4103/singaporemedj.SMJ-2022-229. PMID: 36876621; PMCID: PMC10071861.
Hashtag: #NovoNordisk
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
"Beyond the Scale" campaign builds on Novo Nordisk's long-standing commitment to tackling chronic diseases. With over 100 years of experience advancing care for diabetes and more than 25 years of focused obesity research, Novo Nordisk is pioneering the medical management of obesity and the science of the GLP-1 hormone — a naturally occurring signal that regulates appetite and plays a key role in achieving sustained weight loss.
As part of its mission to drive long-term health outcomes, Novo Nordisk is also investing in scalable prevention efforts. Through the Cities for Better Health initiative — a global public-private partnership spanning over 50 cities — Novo Nordisk is working to reduce chronic disease risk in vulnerable urban communities. Its latest programme, the Childhood Obesity Prevention Initiative (COPI), delivers targeted interventions to promote healthier diets and physical activity among children aged 6–13 in underserved areas.
In Singapore and beyond, these initiatives reinforce Novo Nordisk's holistic approach: treating obesity with medicine and empathy today, while building healthier environments for the next generation.
For more information, visit novonordisk.sg.
Novo Nordisk
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
Stronger Health Through Smarter Taxes in Mauritius
WHO has joined forces with VISA NGO and the University of Cape Town to assess the impact of increasing health taxes in Mauritius. Using a simulation tool, the study examined how tax hikes affect tobacco use, government revenues, and premature deaths. A 15% annual cigarette tax increase could: Boost excise revenue by 55% Reduce smoking prevalence from 18.1% to 17.4% Prevent 11,600 premature deaths by 2029 Even more ambitious action—a 25% annual increase—could: Double excise revenues Lower smoking prevalence to 16.3% Save 19,300 lives by 2029 On 20 June 2025, WHO convened high-level officials from the Ministries of Health and Finance to discuss the findings, presented by the University of Cape Town's Research Unit on the Economics of Excisable Products and a WHO taxation expert. WHO and VISA echoed the study's call for regular, significant tax increases—one of the most effective ways to curb noncommunicable diseases (NCDs) Earlier, on 26 May, VISA and WHO presented the findings to key stakeholders including the Mauritius Revenue Authority, Ministries of Education and Youth, the University of Mauritius, NGOs, and consumer groups. WHO also applauded the Government's recent decision to raise taxes by 10% on tobacco and alcohol, and 100% on sugary drinks, extending it to products like chocolate and ice cream. 'This is a gift to public health,' said Dr. Anne Ancia, WHO Representative. 'Higher prices on unhealthy products help reduce consumption—especially in a country where obesity, diabetes and cardio-vascular diseases are leading causes of death and disability.' Dr. Ancia also stressed the urgent need to enforce the Tobacco Law 2022, particularly the ban on single-stick sales, which undermines progress in reducing tobacco use through higher prices. Distributed by APO Group on behalf of World Health Organization (WHO) - Mauritius.
Zawya
a day ago
- Zawya
Stung by high prices, Americans make their own weight-loss drugs
In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved for sale by the U.S. Food and Drug Administration. One comes mixed with tirzepatide, the active ingredient in Eli Lilly's Zepbound. Spencer, 50, is not part of any drug trial but mixes the cocktails herself, using tiny doses that she believes are safe. The total cost is about $50 monthly, as little as one-tenth of what she would expect to pay their makers for full treatment. The drugs – glucagon-like peptide-1 (GLP-1) weight-loss medicines – are manufactured and shipped from China, according to the packaging. She orders them through online vendors. Spencer belongs to a fast-growing group of Americans turning to what many call the "gray market" for obesity medicines, bringing cheap active ingredients from China often labeled as for research purposes, according to import data and social media postings. It's a trend that drugmakers Lilly and Novo Nordisk, which makes Wegovy, say is dangerous as well as illicit. Reuters tracked online forums and interviewed seven people who said they bought obesity medicines through this market, including an attorney in Arizona who works for a state insurance agency, a retired nurse in Illinois and a Type 1 diabetic in Louisiana, who said the medicine helped cut her insulin intake by more than half. For more than a year there has been demand for cheap Chinese-made powders, exacerbated by limited health insurance coverage in the U.S. Buyers told Reuters the gray market received a boost from an FDA ruling last year that U.S. compounding pharmacies – outsourcing facilities that create drugs in shortage – must stop selling obesity medicines more cheaply than the companies that developed them. Shipments of such active ingredients from Chinese entities not registered with the FDA jumped by 44% in January from the previous month, according to research by the Partnership for Safe Medicines, a public health group focused on the safety of prescription drugs. It said its findings are likely an undercount, because unregistered vendors may not disclose that their parcels contain medicines. Packages valued at less than $800 that enter the U.S. under the de minimis rule are not included in the data. Nearly three-quarters of U.S. adults are overweight or obese, according to government estimates, but a survey by nonprofit health policy research organization KFF found only about 8% say they have taken medicine for weight loss. Most of the gray market buyers Reuters interviewed had told their medical providers they were taking GLP-1 medicines but not where or how they bought them. Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to consulting firm Mercer. Many Americans have paid out of pocket for cheaper compounded drugs. Interest in taking small doses of the drugs has also spurred the online marketplace, buyers said. Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny. They swap advice for navigating the market, exchanging information on vendors, shipping and dosage, and sometimes clubbing together to cover the cost of testing the powders. One forum is called StairwayToGray. It has more than 21,000 members on Telegram and recently was gaining nearly 1,000 members weekly. It did not respond to Reuters' inquiries, and blocked access to the forum after receiving them. It has a website where it says it does not facilitate group purchases. "This community is filling the gaps and being our own regulators, ensuring testing and access for everyone who needs it. Because you shouldn't have to choose between your health or your wallet," it says. Spencer stores her stocks in her fridge and makes them up in the kitchen – carefully measuring sterile water, rolling the vial between her fingers until the powder dissolves, and drawing the liquid into a syringe before injecting it into her thigh or belly. She has lost 24 pounds. "This is working so well for me. It's so easy. It's cheap," said Spencer, who assumes her health plan wouldn't cover the drugs. "I don't know what I would do without this medicine." "VERY DANGEROUS" In February, 38 U.S. state and territory attorney generals wrote the FDA seeking action against illegally sold weight-loss medicines, including "research purposes only" ingredients from China. "Much like with counterfeit versions, these active ingredients come from unregulated, undisclosed sources ... and pose risks of contamination and inclusion of foreign substances," they said. Shabbir Safdar, executive director of the Partnership for Safe Medicines, said unapproved drugs can have problems with sterility, purity and consistency. "It can be very dangerous. You're playing the role of your own doctor, pharmacist, and FDA inspector," he said. Of those interviewed, only Spencer reported any problems: She once got her math wrong and overdosed, resulting in several days of severe flu-like symptoms. Lilly said it had taken many steps to address patient safety risks posed by the proliferation of unsafe or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working with social media companies to identify and remove posts that promote unsafe products, including those described as "research use only." "We will continue to take action to stop those who threaten patient safety and urgently call on regulators and law enforcement to do the same," a Lilly spokesperson told Reuters. Novo Nordisk also said it continues to take action against entities that violate laws and regulations and put patient safety at risk. America's Poison Control agency, which maintains the nation's poison data surveillance system and monitors GLP-1 exposures, said it could not reliably track cases involving unregulated "research chemical powders" because they are sold under various names and formulations. The FDA's goal is to stop illegal sales of pharmaceutical medicines at the border, said George Karavetsos, former director of the FDA's Office of Criminal Investigations and co-author of the imports study. But understanding the true nature and intended use of small parcels arriving from China can be difficult, and the FDA rarely seeks charges against consumers for personal use, he said. The FDA said it urges consumers to buy from licensed pharmacies and "avoid products of unknown quality," adding it was actively protecting consumers by intercepting illegal products at ports, and warning companies that market unapproved weight-loss medicines, including those mislabeled as "for research purposes." Although the forums show suppliers purportedly in China, Reuters was not able to verify where the drugs originate. None of the vendors responded to requests for comment. A Reddit spokesperson said the site prohibits facilitating transactions involving drugs and it had shut down a group found to be doing this. Telegram said it removes "more than a million" instances of harmful content each day, but did not comment directly. MICRODOSE MISTAKE Spencer has polycystic ovary syndrome and for years struggled with weight gain and hypertension. She decided to try obesity medicines after seeing claims on social media that microdosing them could give fewer side effects, and bought semaglutide, the active ingredient in Wegovy, from a compounding pharmacy for about $200 per month. She started on one-fifth of the lowest dose. Within days, intermittent joint pain she often suffered had dissipated: "I didn't realize how badly I hurt until the pain was gone." The cost would reach about $500 a month if she bought the drug from Novo, which recently introduced one-off discounts. After a week, Spencer said, her blood pressure dropped so low she thought she might pass out, so she stopped taking hypertension medicine. Her pressure stabilized and she lost three pounds. She wanted to understand more about microdosing, and turned to the gray market last summer. On Reddit, users told how another Novo drug in development, called CagriSema, had helped reduce inflammation and hunger pangs better than semaglutide. CagriSema is Novo's next-generation obesity drug candidate, still in clinical trials so not available to the public. It combines semaglutide with another molecule, called cagrilintide, which intensifies the hormone-mimicking effects to regulate blood sugar and reduce hunger. Spencer was intrigued. She found a U.S. reseller saying they tested Chinese-made CagriSema through a third-party lab before selling it to Americans. On microdoses of CagriSema, Spencer could enjoy food in small quantities. "I could say 'yes' because I knew I was only going to eat four bites." In October, Spencer saw on Reddit that tirzepatide might also reduce inflammation. She placed a new order for vials that contained cagrilintide and tirzepatide combined, dubbed "cagri-tirz." Now each Monday, Spencer injects herself with tiny amounts of cagri-tirz. On Thursdays, she uses retatrutide, a new obesity medicine by Lilly, also in trials. As she was switching to cagri-tirz, Spencer made a dangerous mistake. She calculated her new dosage without realizing the concentration of cagrilintide in the combined vials was 10 times higher than she had taken previously. "I was an idiot. I didn't do my math. Or rather, I did the math for the tirzepatide but not for the cagri," she said. Almost immediately, she began vomiting. The reaction was so severe she had trouble moving. She forced herself to drink water but couldn't eat. After four days, when symptoms lifted, she had lost seven pounds. Despite the blunder, Spencer didn't consider returning to compounded versions of the drugs or abandoning them altogether. She is not regularly monitored by a healthcare provider, but says her treatment has led to a "life-changing" reduction in weight, joint pain and blood pressure. "HONOR SYSTEM" Gray-market buyer Marie, 41, shows how do-it-yourself drugmakers are organizing. She describes herself as a "soccer mom" from the Midwest and asked to be identified by her middle name to protect her privacy. Last year she bought a compounding pharmacy's version of tirzepatide, paying about $470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs. She began to worry about her supply. Browsing on Reddit, she discovered links to Telegram and a trove of detailed instructions from experienced users for buying weight-loss drug ingredients from China. Customers said they often paid with Bitcoin or through mobile payment service Venmo. After a month closely following the forums, Marie made a purchase in January. The package that arrived contained 20 small glass vials of white powder with red caps. There were no instructions. The vendor who advertised the package on Telegram said it came from China. Marie returned to the forums and joined a group of 52 other customers who paid a total of $1,020 to a Tennessee-based company called Peptide Test. Six members mailed in a vial each and the others chipped in their share of the fee. The lab found the samples were pure. Peptide Test declined to comment. "It's an honor system," said Marie. "These groups are very supportive in a way I haven't seen on the internet before." Before her first injection, Marie gave her husband details of what she had done. They agreed that if needed, he would disclose everything to the emergency medics. But she was fine. In March, Marie volunteered to organize testing a new order of tirzepatide. The group formed on Telegram after users received vials from the same vendor which they judged to be from the same batch based on the color of the caps. In all, 38 buyers agreed to chip in for the $1,300 bill, and decided by poll that five vials would be enough. Five people sent drugs to the lab, Janoshik Analytical in the Czech Republic, which found the vials contained tirzepatide, as purported, with purity between 99.78% and 99.85%. Janoshik's CEO, Peter Magic, is a former amateur weight-lifter. He said his company started out more than a decade ago testing performance-enhancing drugs for online buyers. Last year, it tested 3,050 samples of obesity drugs, up from just over 650 samples in 2023. "We're testing hundreds of these every week," said Magic, whose company helps customers navigate customs requirements for shipping chemicals. (Reporting by Robin Respaut in San Francisco and Maggie Fick in London; additional reporting by Patrick Wingrove in New York; edited by Sara Ledwith and Michele Gershberg)
Zawya
a day ago
- Zawya
Qatar's health expenditure to surge 14% by 2029
DOHA: Qatar's healthcare industry is poised for rapid expansion, with total health spending projected to grow at a compound annual growth rate (CAGR) of 14 percent by 2029, reaching $11.5bn (QR42bn), according to a recent report by Fitch Solutions. Health experts note that this growth would make Qatar the third-largest healthcare market in the Gulf Cooperation Council (GCC) and the tenth-largest in the Middle East and North Africa (MENA) region. Despite these impressive figures, analysts at Fitch Solutions stress that Qatar's overall market opportunities are challenging compared to other regional players. This is primarily due to the country's small population size and modest short-term economic growth prospects. 'The numbers show a healthy trajectory, but we must be careful not to confuse high growth rates with large-scale opportunity,' said Dr. Lisa Kurian, a Doha-based public health specialist. 'Qatar's small population means we are working with a narrower base, even if spending per capita is among the highest in the region.' Government investment, driven by the National Development Strategy 2024–2030, continues to underpin the growth in public health expenditure. Meanwhile, the private sector is benefiting from strong per capita health spending and ongoing public-private partnerships. 'Qatar has done well to encourage private sector involvement without compromising public oversight,' said Dr. Kurian adding that projects like Surgi Art Hospital are proof that collaboration is driving innovation in patient care. On the other hand, digital transformation is also playing a key role in ensuring efficient healthcare delivery. Government-backed initiatives like the Smart Programme (TASMU) aim to leverage big data, AI, and integrated electronic health records to streamline services and prevent resource bottlenecks. In July 2024, the government signed an agreement with AI firm Lunit to introduce AI-powered breast cancer screening tools across primary health centres—an initiative expected to enhance early detection and reduce long-term costs. 'Investing in AI for diagnostics is not just about innovation—it's about sustainability. Early diagnosis means better outcomes and lower treatment costs, which is critical for long-term health system viability, the medical expert said. She also emphasised that 'Technology cannot replace people. Without well-trained, adequately supported staff, even the most advanced tools will fall short of their potential.' As Qatar positions itself as a leader in high-value healthcare within the region, striking the right balance between innovation, infrastructure, and human capital will be critical. Additionally, researchers highlight that the next phase of development must focus on systemic resilience, ensuring that digital health tools, regulatory frameworks, and a capable workforce work together cohesively to deliver quality care for a changing population. With its strong fiscal position, high per capita income, and strategic vision for healthcare advancement, Qatar is also becoming an increasingly attractive destination for international healthcare companies, investors, and research institutions. © Dar Al Sharq Press, Printing and Distribution. All Rights Reserved. Provided by SyndiGate Media Inc. (
